Here are four things to know.
1. The investor for the Series A funding is Morley Device Innovations, an affiliate of Atlanta-based Morley Research Consortium.
2. As part of the funding round, Morley Managing Director Donald Johnson will join the Life2 board, according to a news release.
3. The release states Life2 will use the $1.5 million to grow sales and to further develop the company’s Length of Stay Optimization Suite.
4. “MDI is experienced in quickly analyzing and validating which medical devices will work and which ones will not work in today’s healthcare market. We have applied this same acumen to the Life2 technology base and quickly concluded we wanted to be early investors,” Mr. Johnson said.
He added: “Life2 has developed and deployed innovative and transformative technology that is needed in the healthcare sector today more than ever. The technology calculates on a daily basis which caregiver actions work and which ones do not during a patient’s hospital stay.”
More articles on healthcare finance:
NYC Health + Hospitals sees operating loss nearly double to $673M
Wellmark executive reveals which condition Iowa’s $12M patient suffers from
NY cancer center avoids Medicare reimbursement cut after $250k typo
